2022 Interim Results Announcement Webinar Invitation
Hua Medicine
Aug 26, 2022

26 August 2022(Friday)


pdf-2.png2022 Interim Results Announcement Webinar Invitation

Dear Investors and Analysts,

Hua Medicine (2552.HK) cordially invites you or your representative to attend the online webinar in relations to the Company’s 2022 interim results, which will be held 9:00 AM GMT+8, 26 August 2022 (Friday).
During the webinar, management will provide a review of the Company’s interim financial results in 2022, business updates, as well as address plans for the future.

Details of the webinar are as follows:





26 August 2022 (Friday)


Login starts:      8:45AM GMT+8
Meeting starts:  9:00AM GMT+8


Approx. 45 mins (including Q&A session)


Dr. Li Chen, CEO, Founder, and Chief Scientific Officer
Mr. George Lin, Chief Financial Officer and Executive Vice President


Registration Link:https://icaasia.zoom.us/webinar/register/WN_1qJJAQo0QCaD19R2NEylZQ

(Please register via the above link no later than 25 August 2022)
1. Registration is invite-only and is subject to company approval.
2. Upon successful registration, a personalized meeting link will be sent to the registered email. Please use the link to access the meeting.


If you have any questions, please send them to huamedicine@icaasia.com before 25 August 2022 (Thursday).
Company management will address the received questions during the Q&A session.Other questions could also be raised during the Q&A session subject to the meeting time.

*If you are intended to attend the Chinese session (10:00AM GMT+8, 26 August), please send an email to huamedicine@icaasia.com for registration. Meeting details will be provided upon confirmation.

About Hua Medicine
Hua Medicine is an innovative drug development company found in China focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global highcaliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. Targeting on glucose sensor glucokinase, dorzagliatin, as its cornerstone product, restores glucose sensitivity in T2D patients and has completed SEED and DAWN registration trials, with its NDA accepted by the National Medical Products Administration (NMPA) in China. This first-in-class glucokinase activator has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.

Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.